Key result
The abstract contains only conflict of interest disclosures and no study results.
Why the study?
Should primary prevention implantable cardioverter defibrillators be used in patients with non-ischaemic cardiomyopathy?
Should primary prevention implantable cardioverter defibrillators be used in patients with non-ischaemic cardiomyopathy?
The paper discusses the role of primary prevention ICDs in non-ischaemic cardiomyopathy, challenging current Australian heart failure guidelines.
The University of Adelaide reports receiving on behalf of Dennis Lau lecture and/or consulting fees from Abbott, Bayer, Biotronik and Pfizer. Prashanthan Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, Abbott, Boston Scientific and CathRx. The University of Adelaide reports receiving on behalf of Prashanthan Sanders lecture and/or consulting fees from Biosense-Webster, Medtronic, Abbott, and Boston Scientific. The University of Adelaide reports receiving on behalf of Prashanthan Sanders research funding from Medtronic, Abbott, Boston Scientific, Biotronik and Liva Nova.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2019) conducted an editorial in non-ischaemic cardiomyopathy. Primary prevention implantable cardioverter defibrillators was evaluated. The abstract contains only conflict of interest disclosures and no study results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: